BACKGROUND:Bone marrow (BM) dysfunction is common in severely injured trauma patients, resulting from elevated catecholamines and plasma granulocyte colony-stimulating factor (G-CSF) as well as prolonged mobilization of hematopoietic progenitor cells (HPCs). We have previously shown that propranolol (β-blocker [BB]) reduces HPC mobilization in a rodent model of injury and hemorrhagic shock. We hypothesize that BB would prevent BM dysfunction in humans following severe injury. METHODS:Forty-five severely injured trauma patients were studied in a prospective, randomized pilot trial. Twenty-five patients received BB, and 20 served as untreated controls. The dose of propranolol was adjusted to decrease the heart rate by 10% to 20% from baseline. Blood was analyzed for the presence of HPC (blast-forming unit erythroid cells [BFU-E] and colony-forming unit erythroid cells) and G-CSF. Demographic data, Injury Severity Score (ISS), hemoglobin, reticulocyte number, and outcome data were obtained. RESULTS:The mean age of the study population was 33 years; 87% were male, with a mean ISS of 29. There is a significant increase in BFU-E in peripheral blood immediately following traumatic injury, and this mobilization persists for 30 days. The use of BB significantly decreases BFU-E and colony-forming unit erythroid cells at all time points. G-CSF is significantly elevated in both groups on admission; the use of BB decreases G-CSF levels by 51% as compared with 37% for controls. The average hemoglobin is nearly 1 g higher on the day of discharge with propranolol treatment (BB, 9.9 ± 0.4 g/dL vs. no BB, 9.1 ± 0.6 g/dL). CONCLUSION: Following severe trauma, early treatment with propranolol following resuscitation is safe. The use of propranolol blunts early tachycardia, reduces HPC mobilization, and results in a faster return to baseline of the G-CSF peak seen after injury. There is also a trend toward faster recovery and resolution of anemia. Propranolol may be the first therapeutic agent to show improved BM function after severe injury. LEVEL OF EVIDENCE: Therapeutic study, level III.
RCT Entities:
BACKGROUND: Bone marrow (BM) dysfunction is common in severely injured traumapatients, resulting from elevated catecholamines and plasma granulocyte colony-stimulating factor (G-CSF) as well as prolonged mobilization of hematopoietic progenitor cells (HPCs). We have previously shown that propranolol (β-blocker [BB]) reduces HPC mobilization in a rodent model of injury and hemorrhagic shock. We hypothesize that BB would prevent BM dysfunction in humans following severe injury. METHODS: Forty-five severely injured traumapatients were studied in a prospective, randomized pilot trial. Twenty-five patients received BB, and 20 served as untreated controls. The dose of propranolol was adjusted to decrease the heart rate by 10% to 20% from baseline. Blood was analyzed for the presence of HPC (blast-forming unit erythroid cells [BFU-E] and colony-forming unit erythroid cells) and G-CSF. Demographic data, Injury Severity Score (ISS), hemoglobin, reticulocyte number, and outcome data were obtained. RESULTS: The mean age of the study population was 33 years; 87% were male, with a mean ISS of 29. There is a significant increase in BFU-E in peripheral blood immediately following traumatic injury, and this mobilization persists for 30 days. The use of BB significantly decreases BFU-E and colony-forming unit erythroid cells at all time points. G-CSF is significantly elevated in both groups on admission; the use of BB decreases G-CSF levels by 51% as compared with 37% for controls. The average hemoglobin is nearly 1 g higher on the day of discharge with propranolol treatment (BB, 9.9 ± 0.4 g/dL vs. no BB, 9.1 ± 0.6 g/dL). CONCLUSION: Following severe trauma, early treatment with propranolol following resuscitation is safe. The use of propranolol blunts early tachycardia, reduces HPC mobilization, and results in a faster return to baseline of the G-CSF peak seen after injury. There is also a trend toward faster recovery and resolution of anemia. Propranolol may be the first therapeutic agent to show improved BM function after severe injury. LEVEL OF EVIDENCE: Therapeutic study, level III.
Authors: Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette Journal: Cell Date: 2006-01-27 Impact factor: 41.582
Authors: Saman Arbabi; Eric M Campion; Mark R Hemmila; Melissa Barker; Mary Dimo; Karla S Ahrns; Andreas D Niederbichler; Kyros Ipaktchi; Wendy L Wahl Journal: J Trauma Date: 2007-01
Authors: David H Livingston; Devashish Anjaria; Jonathan Wu; Carl J Hauser; Victor Chang; Edwin A Deitch; Pranela Rameshwar Journal: Ann Surg Date: 2003-11 Impact factor: 12.969
Authors: Saman Arbabi; Karla S Ahrns; Wendy L Wahl; Mark R Hemmila; Stewart C Wang; Mary-Margaret Brandt; Paul A Taheri Journal: J Trauma Date: 2004-02
Authors: Gregg M Baranski; Latha V Pasupuleti; Ziad C Sifri; Kristin M Cook; Walter D Alzate; Pranela Rameshwar; David H Livingston; Alicia M Mohr Journal: J Bone Marrow Res Date: 2013
Authors: Ines G Alamo; Kolenkode B Kannan; Michael A Smith; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2016-10 Impact factor: 3.313
Authors: Ines G Alamo; Kolenkode B Kannan; Letitia E Bible; Tyler J Loftus; Harry Ramos; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2017-04 Impact factor: 3.313
Authors: Ines G Alamo; Kolenkode B Kannan; Harry Ramos; Tyler J Loftus; Philip A Efron; Alicia M Mohr Journal: Surgery Date: 2016-10-11 Impact factor: 3.982
Authors: Elizabeth S Miller; Tyler J Loftus; Kolenkode B Kannan; Jessica M Plazas; Philip A Efron; Alicia M Mohr Journal: J Surg Res Date: 2019-06-14 Impact factor: 2.192
Authors: Natalie E Riddell; Victoria E Burns; Graham R Wallace; Kate M Edwards; Mark Drayson; Laura S Redwine; Suzi Hong; Jack C Bui; Johannes C Fischer; Paul J Mills; Jos A Bosch Journal: Brain Behav Immun Date: 2015-03-06 Impact factor: 7.217
Authors: Tyler J Loftus; Kolenkode B Kannan; Christy S Carter; Jessica M Plazas; Juan C Mira; Scott C Brakenridge; Christiaan Leeuwenburgh; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2018-03 Impact factor: 3.313
Authors: John G Noel; Benjamin J Ramser; Jose A Cancelas; Francis X McCormack; Jason C Gardner Journal: Exp Hematol Date: 2017-09-01 Impact factor: 3.084
Authors: Sylvia Ojeda; Emily Blumenthal; Pamela Stevens; Clark R Andersen; Lucy Robles; David N Herndon; Walter J Meyer Journal: J Burn Care Res Date: 2018-10-23 Impact factor: 1.845
Authors: Tyler J Loftus; Juan C Mira; Julie A Stortz; Tezcan Ozrazgat-Baslanti; Gabriella L Ghita; Zhongkai Wang; Babette A Brumback; Ricardo F Ungaro; Azra Bihorac; Christiaan Leeuwenburgh; Frederick A Moore; Lyle L Moldawer; Scott C Brakenridge; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2019-02 Impact factor: 3.313
Authors: Elizabeth S Miller; Camille G Apple; Kolenkode B Kannan; Zackary M Funk; Philip A Efron; Alicia M Mohr Journal: Am J Surg Date: 2020-07-25 Impact factor: 2.565